Lemtrada®

Understanding Lemtrada® 

Lemtrada® (alemtuzumab) is a monoclonal antibody therapy used to treat relapsing forms of multiple sclerosis (MS). It works by targeting CD52, a protein found on immune cells, helping to reset the immune system and reduce MS relapses. By depleting and then allowing immune cells to repopulate, Lemtrada® helps decrease disease activity and slow MS progression.

How Lemtrada® Works:

• Targets CD52, a protein found on immune cells, to deplete overactive immune responses.
• Allows the immune system to reset, reducing autoimmune attacks on the nervous system.
• Helps decrease relapses and slow disease progression in relapsing MS.

FDA Approval:

• November 14, 2014 – Approved for the treatment of relapsing forms of multiple sclerosis (MS)

For more information, please visit the Lemtrada® patient website and speak with your healthcare provider to determine if Lemtrada® is the right treatment option for you.